Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

49.03USD
18 Sep 2014
Price Change (% chg)

$0.56 (+1.16%)
Prev Close
$48.47
Open
$48.80
Day's High
$49.10
Day's Low
$48.78
Volume
177,616
Avg. Vol
166,389
52-wk High
$49.10
52-wk Low
$32.59

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap (Mil.): $102,813.30
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.69

Financials

  NVO.N Industry Sector
P/E (TTM): 28.95 32.66 33.47
EPS (TTM): 1.69 -- --
ROI: 65.79 18.15 17.39
ROE: 71.98 18.86 18.25
Search Stocks

NORDIC STOCKS - Factors to watch on Sept 19

HELSINKI, Sept 19 - The following stocks may be affected by newspaper reports and other factors on Friday:

11:35am IST

Novo's Ryzodeg effective in type 2 diabetes treatment: study

COPENHAGEN - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment -study

COPENHAGEN, Sept 18 - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

NORDIC STOCKS-Factors to watch on Sept 17

COPENHAGEN, Sept 17 - The following stocks may be affected by newspaper reports and other factors on Wednesday:

17 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN, Sept 16 - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

Executive view: Novo Nordisk to increase its focus on obesity

COPENHAGEN - Novo Nordisk's liraglutide drug is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration (FDA) said on Thursday.

12 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

UPDATE 2-U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON, Sept 11 - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €88.24 -0.22
Eli Lilly and Co (LLY.N) $66.59 +0.68

Earnings vs. Estimates

Search Stocks